### / IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

: Ries, U. J. et al

) Art Unit: 1614

) Examiner:

U.S. Appln. No.

: 10/051,412

U.S. Filing Date

: 01/17/2002

Confirmation No. : 9079

Title of Invention: Carboxylic Acid Amides Having Antithrombotic Activity

Attny. Docket No.: 5/1313

Commissioner for Patents Washington, D.C. 20231

April 15, 2002

#### TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow.

1.97(b). This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.

1.97(c).	This Statement is being filed after the time period specified in 37
C.F.R. §1.97(b), but 1	pefore the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a
notice of allowance u	nder 37 C.F.R. §1.311, or iii) an action that otherwise closes
prosecution in the ap	plication. This Statement is being accompanied by:

A	statement as	specified in	37 C	C.F.R.	§1.97(e)	[see below	']; or

The fee set forth in 37 C.F.R. §1.17(p).

The Assistant Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.

	ent as s	This Statement is being filed after the period specified in 37 C.F.R. on or before payment of the issue fee. This Statement is accompanied by a specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
	1.97(e	s).
	counte	Each item of information contained in the instant information disclosure nent was first cited in any communication from a foreign patent office in a erpart foreign application not more than three (3) months prior to the filing of stant information disclosure statement; or
	foreig makin inforn C.F.R	No item of information contained in the instant information disclosure nent was cited in a communication from a foreign patent office in a counterpart in application, and, to the knowledge of the person signing this certification after a reasonable inquiry, no item of information contained in the instant nation disclosure statement was known to any individual designated in 37. §1.56(c) more than three (3) months prior to the filing of the instant nation disclosure statement.
		The fee set forth in 37 C.F.R. §1.17(p).
		The Assistant Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
counte in sect	rpart ap	(d). Each item of information contained in the accompanying information tement was cited in a communication from a foreign patent office in a oplication, which communication was not received by any individual designated 6(c) more than thirty (30) days prior to the filing of the accompanying isologure statement.

The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Patent Department

P.O. Box 368

Boehringer Ingelheim Corp. 900 Ridgebury Road

Ridgefield, CT. 06877 Tel.: (203) 798-4868 Respectfully submitted,

Alan R. Stempel

Attorney for Applicant(s)

Reg. No. 28,991

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents Washington, DC 20231

on April 15, 2002

By: Alan R. Stempel

Reg. No. . 28,991



# RECEIVED

APR 2 4 2002

## TECH CENTER 1600/2900

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

#### Complete if Known Substitute for form 1449A/PTO **Application Number** 10/051,412 INFORMATION DISCLOSURE Filing Date 01/17/2002 STATEMENT BY APPLICANT **First Named Inventor** Uwe Joerg RIES 1614 Art Unit (use as many sheets as necessary) **Examiner Name** Attorney Docket Number 5/1313 Sheet of

U.S. PATENT DOCUMENTS							
Examiner Initials		Document Number Number - Kind Code <sup>2</sup> (if known	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		US-	-				
		us-					
		US-		[			
		us-					
		us-					
		US-					
		_us-		<u>.</u>			
		US-					
		US-	<u>.</u>	<u>.</u>			
		US-					
		US-					
		US-					
		US-					
		US-		ĺ			
		US-		<u> </u>			
		US-					
		us-					
		us-	•	ĺ			
İ		us-		ĺ			
Ī		us-					

		FOR	EIGN PATENT D	OCUMENTS		
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
		WO 01 10823	02/15/2001	Bl Pharma KG		
		WO 00 71508	11/30/2000	COR Therapeutics		
		WO 00 71512	11/30/2000	COR Therapeutics	_	
	-				,	
		-				
- •						
İ						

Examiner	·	Date	
Signature		Considered	

Engish language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.